Publicaciones en colaboración con investigadores/as de Centro de Investigación Médica Aplicada (26)

2022

  1. Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies

    Advances in Cancer Research (Academic Press Inc.), pp. 367-413

2021

  1. Paradigms on immunotherapy combinations with chemotherapy

    Cancer Discovery, Vol. 11, Núm. 6, pp. 1353-1367

  2. The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes

    British Journal of Cancer, Vol. 124, Núm. 6, pp. 1138-1149

2020

  1. CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

    Immunity, Vol. 52, Núm. 5, pp. 856-871.e8

  2. Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors

    Science Translational Medicine, Vol. 12, Núm. 565

  3. The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas

    Journal of Clinical Investigation, Vol. 130, Núm. 4, pp. 1879-1895

2019

  1. Clinical presentation, diagnosis and staging of cholangiocarcinoma

    Liver International, Vol. 39, Núm. S1, pp. 98-107

  2. Cytokines in clinical cancer immunotherapy

    British Journal of Cancer, Vol. 120, Núm. 1, pp. 6-15

  3. Genetic mouse models as in vivo tools for cholangiocarcinoma research

    Cancers, Vol. 11, Núm. 12

  4. Inhibitor of differentiation-1 sustains mutant KRAS-driven progression, maintenance, and metastasis of lung adenocarcinoma via regulation of a FOSL1 network

    Cancer Research, Vol. 79, Núm. 3, pp. 625-638

  5. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer

    Drug Safety, Vol. 42, Núm. 2, pp. 281-294

  6. TGFb blockade enhances radiotherapy abscopal efficacy effects in combination with anti-PD1 and anti-CD137 immunostimulatory monoclonal antibodies

    Molecular Cancer Therapeutics, Vol. 18, Núm. 3, pp. 621-631

  7. Vaccination for pancreatic ductal adenocarcinoma: A hard nut to crack

    Clinical Cancer Research, Vol. 25, Núm. 18, pp. 5435-5437

2018

  1. A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis

    Journal for ImmunoTherapy of Cancer, Vol. 6, Núm. 1

  2. Adjuvant therapy for colon cancer: Genes, genes. . . And the patient in the center

    Clinical Cancer Research, Vol. 24, Núm. 16, pp. 3787-3789

  3. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients

    Annals of Oncology, Vol. 29, Núm. 5, pp. 1312-1319

  4. Revisiting interleukin-12 as a cancer immunotherapy agent

    Clinical Cancer Research, Vol. 24, Núm. 12, pp. 2716-2718

2017

  1. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer

    Nature Communications, Vol. 8

  2. Interleukin-8 in cancer pathogenesis, treatment and follow-up

    Cancer Treatment Reviews, Vol. 60, pp. 24-31

2016

  1. Immunotherapy of cancer visualized by live microscopy: Seeing is believing

    Clinical Cancer Research, Vol. 22, Núm. 17, pp. 4277-4279